Tenon(R) Medical Announces the Introduction of the Catamaran(R) SE SI Joint Fusion System
Tenon Medical (NASDAQ:TNON) has announced the alpha launch of its new Catamaran SE SI Joint Fusion System, scheduled for early Q4. This system features a 30% smaller implant compared to the original Catamaran device, offering physicians more options for smaller SI joint anatomy or revising previously treated joints. The SE system also includes a manual drilling option.
Key points:
- Catamaran SE provides choices for varying anatomy and treatment strategies
- Over 700 Catamaran fixation devices have been implanted to date
- The system is based on AO principles of arthrodesis
- Recent positive interim outcomes from the MAINSAIL Study were published
The alpha launch will gather initial user feedback before a broader market introduction.
Tenon Medical (NASDAQ:TNON) ha annunciato il lancio alpha del suo nuovo Catamaran SE SI Joint Fusion System, previsto per l'inizio del quarto trimestre. Questo sistema presenta un impianto più piccolo del 30% rispetto al dispositivo Catamaran originale, offrendo ai medici più opzioni per anatomie dell'articolazione sacro-iliaca di dimensioni ridotte o per la revisione di articolazioni già trattate. Il sistema SE include anche un opzione di perforazione manuale.
Punti chiave:
- Il sistema Catamaran SE offre scelte per anatomie e strategie di trattamento diverse
- Oltre 700 dispositivi di fissazione Catamaran sono stati impiantati fino ad oggi
- Il sistema si basa sui principi AO dell'artrodesi
- Recenti risultati positivi intermedi dello studio MAINSAIL sono stati pubblicati
Il lancio alpha raccoglierà il feedback iniziale degli utenti prima di un'introduzione più ampia sul mercato.
Tenon Medical (NASDAQ:TNON) ha anunciado el lanzamiento alpha de su nuevo Sistema de Fusión de Articulaciones SI Catamaran SE, programado para principios del cuarto trimestre. Este sistema presenta un implante un 30% más pequeño en comparación con el dispositivo Catamaran original, ofreciendo a los médicos más opciones para anatomías de la articulación sacroilíaca más pequeñas o para revisar articulaciones ya tratadas. El sistema SE también incluye una opción de perforación manual.
Puntos clave:
- El Catamaran SE proporciona opciones para anatomías y estrategias de tratamiento variadas
- Se han implantado más de 700 dispositivos de fijación Catamaran hasta la fecha
- El sistema se basa en los principios AO de artrodesis
- Se publicaron resultados intermedios positivos recientes del Estudio MAINSAIL
El lanzamiento alpha recogerá la retroalimentación inicial de los usuarios antes de una introducción más amplia al mercado.
테논 메디컬(NASDAQ:TNON)은 새 카타마란 SE SI 관절 융합 시스템의 알파 출시를 발표했으며, 이는 4분기 초에 예정되어 있습니다. 이 시스템은 원래의 카타마란 장치에 비해 30% 더 작은 임플란트를 특징으로 하여 의사들에게 더 작은 SI 관절 해부학이나 이전에 치료한 관절을 수정할 수 있는 더 많은 옵션을 제공합니다. SE 시스템에는 수동 드릴링 옵션도 포함되어 있습니다.
주요 사항:
- 카타마란 SE는 다양한 해부학적 구조와 치료 전략을 위한 선택지를 제공합니다
- 현재까지 700개 이상의 카타마란 고정 장치가 이식되었습니다
- 시스템은 AO 원칙에 기반한 관절 융합에 기초하고 있습니다
- MAINSAIL 연구의 최근 긍정적인 중간 결과가 발표되었습니다
알파 출시는 보다 넓은 시장 도입 이전에 초기 사용자 피드백을 수집할 것입니다.
Tenon Medical (NASDAQ:TNON) a annoncé le lancement alpha de son nouveau Système de Fusion de l'Articulation SI Catamaran SE, prévu pour le début du quatrième trimestre. Ce système présente un implant <30% plus petit que le dispositif Catamaran d'origine, offrant aux médecins plus d'options pour l'anatomie de l'articulation sacro-iliaque plus réduite ou pour la révision des articulations déjà traitées. Le système SE comprend également une option de perçage manuel.
Points clés :
- Le Catamaran SE offre des choix pour des anatomies et des stratégies de traitement variées
- Plus de 700 dispositifs de fixation Catamaran ont été implantés à ce jour
- Le système est basé sur les principes AO de l'arthrodèse
- Des résultats intermédiaires récents positifs de l'étude MAINSAIL ont été publiés
Le lancement alpha recueillera les premiers retours d'utilisateurs avant une introduction plus large sur le marché.
Tenon Medical (NASDAQ:TNON) hat den Alpha-Start seines neuen Catamaran SE SI Gelenkfusion-Systems bekannt gegeben, der für Anfang des vierten Quartals geplant ist. Dieses System verfügt über ein 30% kleineres Implantat im Vergleich zu dem ursprünglichen Catamaran-Gerät und bietet Ärzten mehr Optionen für kleinere SI-Gelenkanatomien oder für die Überarbeitung zuvor behandelter Gelenke. Das SE-System beinhaltet außerdem eine manuelle Bohroption.
Wichtige Punkte:
- Das Catamaran SE bietet Auswahlmöglichkeiten für unterschiedliche Anatomien und Behandlungsstrategien
- Bis heute wurden über 700 Catamaran-Fixationsgeräte implantiert
- Das System basiert auf den AO-Prinzipien der Arthrodese
- Aktuelle positive Zwischenresultate aus der MAINSAIL-Studie wurden veröffentlicht
Der Alpha-Start wird erstes Nutzerfeedback sammeln, bevor eine breitere Markteinführung erfolgt.
- Introduction of Catamaran SE SI Joint Fusion System with 30% smaller implant size
- Manual drilling option added for physicians preferring hand drilling or lacking power sources
- Over 700 Catamaran fixation devices implanted to date
- Positive interim outcomes from MAINSAIL Study recently published
- None.
Insights
The introduction of Tenon Medical's Catamaran SE SI Joint Fusion System represents a significant advancement in sacroiliac joint treatment options. The 30% reduction in implant size addresses a important need for patients with smaller anatomies or those requiring revision surgeries. This product line extension demonstrates Tenon's commitment to market responsiveness and innovation.
The addition of a manual drilling option expands the device's versatility, potentially increasing its adoption in various healthcare settings. With
The Catamaran SE's design, adhering to AO principles of arthrodesis, is a notable strength. Its focus on joint preparation, rigid fixation and bone graft augmentation aligns with best practices in orthopedic surgery. The minimally invasive inferior-posterior approach is particularly interesting, as it may lead to reduced patient recovery times and potentially better outcomes.
The system's MRI compatibility is a significant advantage, allowing for easier post-operative monitoring. However, long-term studies will be important to fully assess the device's efficacy in achieving successful fusions. The positive interim outcomes from the MAINSAIL study are encouraging, but continued vigilance on patient outcomes will be essential.
Tenon Medical's expansion of the Catamaran product line could potentially drive revenue growth and market share gains in the SI joint fusion market. The alpha launch strategy allows for controlled product rollout and refinement based on user feedback, potentially mitigating risks associated with full-scale launches.
However, investors should note that the impact on financials may not be immediate due to the initial release. The company's ability to scale production and navigate regulatory pathways for broader market access will be crucial. While the innovation is promising, Tenon's NASDAQ:TNON stock performance will likely depend on successful commercialization and adoption rates in the coming quarters.
~ New SI Joint Fixation Device Offers a
~The SE System Can Also Be Utilized with a Manual Drilling Option During Implant Preparation~
LOS GATOS, CA / ACCESSWIRE / September 12, 2024 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a company transforming care for patients suffering from certain Sacroiliac Joint (SIJ) disorders, today announced preparation for the initial alpha launch of the Company's new Catamaran SE SI Joint Fusion System targeted for the beginning of Q4. The Catamaran SE Fixation Device extends the line of implant offerings for physicians preferring a smaller Catamaran implant when performing a SI joint fusion procedure. The new implant offers a
The alpha launch of the Catamaran SE will provide important initial user feedback from a select group of physician users to support a broader market launch in the coming months. This news of the Catamaran SE comes on the recent announcement by the Company of the Catamaran SI Joint Fusion System MAINSAIL Study's positive interim outcomes publication. Click here to view the publication in its entirety.
The Catamaran and Catamaran SE SI Joint Fixation devices are single robust fully MRI compatible titanium implants comprised of two pontoons, connected by an osteotome bridge, which is designed to transfix the SI joint along its longitudinal axis providing immediate fixation and stabilization of the joint, with the aim of achieving a successful long-term fusion. The Catamaran implant was developed with respect to AO principles of arthrodesis including 1) adequate joint preparation, 2) rigid fixation and stabilization, and 3) adequate bone graft augmentation. Via a minimally invasive inferior-posterior approach the Catamaran & Catamaran SE implant are delivered within the dense cortical bone of the sacrum and ilium, to transfix and stabilize the SI joint for the treatment of SIJ dysfunction. To date there have been over 700 Catamaran fixation devices implanted to treat primary SI Joint dysfunction and sacroiliitis, as well as revise previously treated SI joints with failed alterative SI joint implants.
Bryan Hoelzer, MD, Interventional Pain Physician and Medical Director of Southwest Spine and Pain Center, in Provo, UT., commented, "The clinical evidence validating the safety and efficacy of the inferior-posterior approach to treat SI Joint disease continues to grow with the recent Catamaran MAINSAIL Study publication. Continued advancement in implant technology as seen in the smaller Catamaran SE Fixation Device is exciting and will provide more improved options for myself and, my patients in treating and managing their painful SI joint disorders."and the entire interventional pain community."
Steven M. Foster, President and CEO of Tenon Medical, stated, "As a leader in the SI joint fusion market it is critical that we continually listen to input from our customers and respond with innovative technology that benefits their patients. The development and introduction of the Catamaran SE SI Joint Fusion System will provide our physician users with more choices to treat their patients with SI Joint disease. We look forward to a successful limited alpha launch and then move rapidly to a full market introduction."
About Tenon Medical, Inc.
Tenon Medical, Inc., a medical device company formed in 2012, has developed The Catamaran SI Joint Fusion System that offers a novel, less invasive approach to the SI joint using a single, robust titanium implant. The system features the Catamaran™ Fixation Device which passes through both the axial and sagittal planes of the ilium and sacrum, stabilizing and transfixing the SI Joint along its longitudinal axis. The angle and trajectory of the Catamaran surgical approach is also designed to provide a pathway away from critical neural and vascular structures and into the strongest cortical bone. Since the national launch of the Catamaran SI Joint Fusion System in October 2022 Tenon is focused on two commercial opportunities with its System in the SI Joint market which includes: 1) Primary SI Joint procedures, and 2) Revision procedures of failed SI Joint implants. For more information, please visit https://www.tenonmed.com/.
The Tenon Medical logo Tenon Medical, and Catamaran are registered trademarks of Tenon Medical, Inc. MAINSAIL is a trademark of Tenon Medical
Safe Harbor
This press release contains "forward-looking statements," which are statements related to events, results, activities, or developments that Tenon expects, believes, or anticipates will or may occur in the future. Forward-looking often contains words such as "intends," "estimates," "anticipates," "hopes," "projects," "plans," "expects," "seek," "believes," "see," "should," "will," "would," "target," "aims," and similar expressions and the negative versions thereof. Such statements are based on Tenon's experience and perception of current conditions, trends, expected future developments and other factors it believes are appropriate under the circumstances, and speak only as of the date made. Forward-looking statements are inherently uncertain and actual results may differ materially from assumptions, estimates or expectations reflected or contained in the forward-looking statements as a result of various factors. For details on the uncertainties that may cause our actual results to be materially different than those expressed in our forward-looking statements, please review our Annual Report on 10-K on file with the Securities and Exchange Commission at www.sec.gov, particularly the information contained in the section entitled "Risk Factors". We undertake no obligation to publicly update or revise any forward-looking statements to reflect new information or future events or otherwise unless required by law.
IR Contact:
Shannon Devine / Rory Rumore
203-741-8811
MZ North America
tenon@mzgroup.us
SOURCE: Tenon Medical, Inc.
View the original press release on accesswire.com
FAQ
What is the new product Tenon Medical (TNON) is launching?
When is Tenon Medical (TNON) planning to launch the Catamaran SE system?
What are the key features of the Catamaran SE SI Joint Fusion System by Tenon Medical (TNON)?